Aethlon Medical, Inc.

AI-generated fair value estimate for this company.

Method: Risk-adjusted deal-value NPV (not a going-concern DCF): on 9/17/26 Aethlon signed a definitive all-stock reverse merger with North Immunology plus a $180M PIPE, creating pro forma equity value of ~$346.5M with legacy Aethlon holders retaining ~4.75% (~$23.14/share fully-diluted deal value); apply 90% probability of closing discounted ~5 months at a 12% special-situation rate (~$19.86), blended with a 10% scenario of deal break reverting to a standalone cash-shell value (~$1.50/share) giving ~$20.01/share.

Reasoning: AEMD is not viable as a standalone going-concern DCF (pre-revenue, cash-burning, prior going-concern language) but its value is now dominated by disclosed, definitive merger economics rather than its legacy Hemopurifier pipeline, so a probability- and time-discounted deal-NPV using the actual signed deal terms is the rigorous approach.